Cancer is one of the most devastating human diseases. Experimental cancer models are important to gain insight into the complex interplay of different cell types and genes in promoting tumor progression and to provide a platform for testing the efficacy of different therapeutic approaches. One of the most commonly used experimental inflammatory cancer models is the DMBA-TPA two-stage skin carcinogenesis model. Tumor formation is induced in this model by the topical application of two different chemicals, 7,12-dimethylbenz[a]anthracene (DMBA) and 12-O-tetradecanoyl phorbol-13-acetate (TPA), that together cause papilloma formation in the skin. As the primary outcome is papilloma formation in the skin, the model is an ideal, reliable, and reproducible way to address both tumor initiation (tumor-free survival) and tumor progression (number and size of visible tumors). The effects of the DMBA-TPA treatment are transmitted via an inflammatory mechanism, which makes this model especially suitable for studying the role of the immune system in tumor formation. However, this model is restricted to the skin and other surfaces where the chemicals can be applied on. A detailed protocol is provided in this article to use the model successfully.

Download full-text PDF

Source
http://dx.doi.org/10.3791/60445DOI Listing

Publication Analysis

Top Keywords

skin carcinogenesis
8
carcinogenesis model
8
12-o-tetradecanoyl phorbol-13-acetate
8
cancer models
8
tumor progression
8
tumor formation
8
papilloma formation
8
formation skin
8
model
7
tumor
5

Similar Publications

: With the rise in prevalence of diagnostic genetic techniques like RNA sequencing and whole exome sequencing (WES), as well as biological treatment regiments for cancer therapy, several genes have been implicated in carcinogenesis. This review aims to update our understanding of the Neurofibromatosis 2 (NF2) gene and its role in the pathogenesis of various cancers. : A comprehensive search of five online databases yielded 43 studies that highlighted the effect of sporadic NF2 mutations on several cancers, including sporadic meningioma, ependymoma, schwannoma, mesothelioma, breast cancer, hepatocellular carcinoma, prostate cancer, glioblastoma, thyroid cancer, and melanoma.

View Article and Find Full Text PDF

Background/objective: Ultraviolet (UV) B radiation leads to DNA damage by generating cyclobutane pyrimidine dimers (CPDs). UVB-induced CPDs can also result in immune suppression, which is a major risk factor for non-melanoma skin cancer (NMSC). UVB-induced CPDs are repaired by nucleotide repair mechanisms (NER) mediated by xeroderma pigmentosum complementation group A (XPA).

View Article and Find Full Text PDF

Green Tea Catechins and Skin Health.

Antioxidants (Basel)

December 2024

Tea Research Institute, Zhejiang University, #866, Yuhangtang Road, Hangzhou 310058, China.

Green tea catechins (GTCs) are a group of bioactive polyphenolic compounds found in fresh tea leaves ( (L.) O. Kuntze).

View Article and Find Full Text PDF

While the genetic paradigm of cancer etiology has proven powerful, it remains incomplete as evidenced by the widening spectrum of non-cancer cell-autonomous "hallmarks" of cancer. Studies have demonstrated the commonplace presence of high oncogenic mutational burdens in homeostatically-stable epithelia. Hence, the presence of driver mutations alone does not result in cancer.

View Article and Find Full Text PDF

In Search for Inhibitors of Human Aldo-Keto Reductase 1B10 (AKR1B10) as Novel Agents to Fight Cancer and Chemoresistance: Current State-of-the-Art and Prospects.

J Med Chem

January 2025

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno D'Alcontres, 31-98166 Messina, Italy.

Article Synopsis
  • AKR1B10 is a human enzyme that reduces carbonyl compounds to alcohols, primarily found in the gastrointestinal tract for detoxifying harmful substances.
  • It is linked to various cancers and precancerous conditions, serving as a significant indicator for tumor development and resistance to anticancer drugs.
  • Researchers are investigating AKR1B10 as a promising target for new treatments aimed at combating cancer and drug resistance, as well as its role in noncancerous diseases.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!